

Huntington Disease, Molecular Analysis, Varies

1-800-533-1710

HAD

| Patient ID<br>SA00000808                    | Patient Name SAMPLEREPDMGLM, VLD20150713A0068 |                                   | Birth Date<br>1981-01-01 | Gender<br>M | Age<br><b>34</b> |
|---|---|-----------------------------------|--------------------------|-------------|------------------|
| Order Number<br>SA00000808                  | Client Order Number SA00000808                | Ordering Physician CLIENT, CLIENT | Report Notes             |             |                  |
| Account Information C7028846 DLMP Rochester |   | Collected<br>12 Jul 2015 14:55    |                          |             |                  |

## **Huntington Disease Analysis**

| Result Summary MCR  | ClinGen. This may not be applicable for all tests.   |  |  |
|---|--|--|--|
| FULL MUTATION IDENTIFIED  | Test results should be interpreted in the context of clinical findings, family history, and other laboratory data.   |  |  |
| Result MCR  | Misinterpretation of results may occur if the information provided   |  |  |
| CAG repeat: 45 (Full penetrance) and 13   | is inaccurate or incomplete.   |  |  |
| Interpretation I MCR<br>This result is consistent with a diagnosis of Huntington disease.   | Rare polymorphisms exist that could lead to false-negative or false-positive results. If results obtained do not match the clinical findings, additional testing should be considered.   |  |  |
| Identification of a mutation has important implications for family<br>members. Testing of at risk individuals is possible, but it is<br>recommended that predictive testing be performed in<br>conjunction with appropriate pre- and post-test counseling.<br>A genetic consultation may be of benefit.<br><b>ADDITIONAL INFORMATION</b><br>A PCR-based assay was utilized to detect CAG repeat<br>expansions in exon 1 of the HTT gene. We estimate that the<br>number of CAG repeats is correct within ±5%. | Bone Marrow transplants from allogenic donors will interfere with testing. Call Mayo Clinic Laboratories for instructions for testing patients who have received a bone marrow transplant.<br>Multiple in-silico evaluation tools may have been used to assist in the interpretation of these results. Of note, the sensitivity and specificity of these tools for the determination of pathogenicity is currently unvalidated.<br>Reason for Referral MCR Evaluation for a diagnosis of Huntington disease (HD). Test for |  |  |
| Normal: <27<br>Intermediate: 27–35<br>Reduced penetrance: 36–39   | the presence of an expansion in the HTT gene.  Specimen  WB Whole Blood  |  |  |
| Full penetrance: >39<br>An online research opportunity called GenomeConnect<br>(genomeconnect.org), a project of ClinGen, is available for the<br>recipient of this genetic test. This patient registry collects de-  | Released By MCR<br>EMILY LAUER   |  |  |
| identified genetic and health information to advance the<br>knowledge of genetic variants. Mayo Clinic is a collaborator of   | Received:         13 Jul 2015 20:20         Reported:         24 Jul 2015 12:47  |  |  |

## **Laboratory Notes**

(1) This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

## **Performing Site Legend**

| MCR Mayo Clinic Laboratories - Rochester Main Campus 200 First Street SW, Rochester, MN 55905 William G. Morice M.D. Ph.D 24D0404292 | Code | Laboratory                                       | Address                                  | Lab Director                | <b>CLIA Certificate</b> |
|--|------|--|--|-----------------------------|-------------------------|
|  | MCR  | Mayo Clinic Laboratories - Rochester Main Campus | 200 First Street SW, Rochester, MN 55905 | William G. Morice M.D. Ph.D | 24D0404292              |

## Report Status: Final

Received and reported dates and times are reported in US Central Time.